<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03512132</url>
  </required_header>
  <id_info>
    <org_study_id>DUVILLARD 2017</org_study_id>
    <nct_id>NCT03512132</nct_id>
  </id_info>
  <brief_title>Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy</brief_title>
  <acronym>DID&amp;NEPHRO</acronym>
  <official_title>Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A number of arguments suggest that the deterioration in high density lipoproteins (HDL)
      functioning may worsen with the development of nephropathy during type 1 diabetes (T1D).

      The objective of this study will be to investigate to what extent nephropathy in T1D patients
      in the microalbuminuria and macroalbuminuria stages, compared to T1D patients without
      nephropathy, is associated with an alteration in HDL functionality and changes in HDL size
      and composition (lipids with detailed study of phosphates and sphingolipids, main
      lipoproteins, inflammatory markers).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ability to induce cholesterol efflux</measure>
    <time_frame>inclusion</time_frame>
    <description>amount of cholesterol captured from cells expressed as %.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nitric oxide synthesis</measure>
    <time_frame>inclusion</time_frame>
    <description>variation in the presence of HDL compared to the basal state, i.e. in the absence of HDL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-inflammatory effect</measure>
    <time_frame>inclusion</time_frame>
    <description>variation in the expression of adhesion molecules (VCAM-1 [vascular cell adhesion molecule 1], ICAM-1 [InterCellular Adhesion Molecule 1] and E selectin) under the influence of TNF-alpha [Tumor Necrosis Factor alpha] in the presence of HDL compared to the absence of HDL.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>T1D with normal albumin levels</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>T1D with microalbuminuria</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>T1D with macroalbuminuria</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>5 EDTA tubes of 7ml and 1 dry tube of 7 ml taken on an empty stomach</description>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>T1D with normal albumin levels</arm_group_label>
    <arm_group_label>T1D with microalbuminuria</arm_group_label>
    <arm_group_label>T1D with macroalbuminuria</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Urine sample</intervention_name>
    <description>Urine sample on an empty stomach</description>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>T1D with normal albumin levels</arm_group_label>
    <arm_group_label>T1D with microalbuminuria</arm_group_label>
    <arm_group_label>T1D with macroalbuminuria</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients treated in the Endocrinology, Diabetology or Nephrology departments of the CHU
        Dijon Bourgogne or in local nephrology or diabetology practices
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        INCLUSION CRITERIA GROUP C (CONTROLS) :

          -  age &gt; 18 years

          -  a person who has given oral consent

          -  Non-diabetics

          -  Fasting plasma glucose &lt; 6.10 mmol/L (1.1 g/L)

          -  Triglyceridemia &lt; 1.7 mmol/L (1.5 g/l)

          -  HDL-C concentration &gt; 1.30 mmol/L (for women and 1.03 mmol/L for men)

          -  Glomerular filtration flow rate &gt; 90 mL/min/1.73m2 (These thresholds correspond to the
             standard thresholds for these parameters)

        INCLUSION CRITERIA GROUP T1D-N (WITH NORMAL ALBUMINURIA) :

          -  age &gt; 18 years

          -  a person who has given oral consent

          -  Diabetic type 1 (based on the patient's clinical history and/or the presence of
             anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5
             ng/l)

          -  HbA1c between 6 and 9%.

          -  normal albuminuria (albumin/creatinine ratio &lt; 2.5 mg/mmol in men and &lt; 3.5 in women)

          -  glomerular filtration rate &gt; 90 mL/min/1.73m2

        INCLUSION CRITERIA GROUP T1D-MICRO (WITH MICROALBUMINURIA)

          -  age &gt; 18 years

          -  a person who has given oral consent

          -  Diabetic type 1 (based on the patient's clinical history and/or the presence of
             anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5
             ng/l)

          -  HbA1c between 6 and 9%.

          -  Microalbuminuria (albumin/creatinine ratio &gt; 2.5 mg/mmol in men and &gt; 3.5 in women,
             and &lt; 30 mg/mmol)

          -  glomerular filtration rate &gt; 90 mL/min/1.73m2

        INCLUSION CRITERIA GROUP T1D-MACRO (WITH MACROALBUMINURIA)

          -  age &gt; 18 years

          -  a person who has given oral consent

          -  Diabetic type 1 (based on the patient's clinical history and/or the presence of
             anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5
             ng/l)

          -  HbA1c between 6 and 9%.

          -  Macroalbuminuria (albumin/creatinine ratio &gt; 30 mg/mmol)

          -  glomerular filtration rate &gt; 45 mL/min/1.73m2

        Exclusion Criteria:

          -  Protected adult

          -  Patient not affiliated to a social security scheme

          -  Pregnant or breastfeeding woman

          -  Drugs interfering with lipid metabolism outside insulin for DT1 : hypolipidemic,
             corticosteroid, estroprogestogens, retinoic acid, antiproteases.

          -  BMI &gt; 30 kg/m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chu Dijon Bourogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence DUVILLARD</last_name>
      <phone>03.80.29.34.53</phone>
      <email>laurence.duvillard@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

